These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Diagnostic investigation and multidisciplinary management in motor neuron disease. Rocha JA; Reis C; Simões F; Fonseca J; Mendes Ribeiro J J Neurol; 2005 Dec; 252(12):1435-47. PubMed ID: 16362828 [TBL] [Abstract][Full Text] [Related]
4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [TBL] [Abstract][Full Text] [Related]
5. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. Talman P; Duong T; Vucic S; Mathers S; Venkatesh S; Henderson R; Rowe D; Schultz D; Edis R; Needham M; Macdonnell R; McCombe P; Birks C; Kiernan M BMJ Open; 2016 Sep; 6(9):e012054. PubMed ID: 27694488 [TBL] [Abstract][Full Text] [Related]
6. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. Goyal NA; Mozaffar T Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719 [TBL] [Abstract][Full Text] [Related]
7. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Mitsumoto H; Brooks BR; Silani V Lancet Neurol; 2014 Nov; 13(11):1127-1138. PubMed ID: 25316019 [TBL] [Abstract][Full Text] [Related]
8. Amyotrophic Lateral Sclerosis: An Update for 2018. Oskarsson B; Gendron TF; Staff NP Mayo Clin Proc; 2018 Nov; 93(11):1617-1628. PubMed ID: 30401437 [TBL] [Abstract][Full Text] [Related]
9. Disease-modifying therapies in amyotrophic lateral sclerosis. Chiò A; Mazzini L; Mora G Neuropharmacology; 2020 May; 167():107986. PubMed ID: 32062193 [TBL] [Abstract][Full Text] [Related]
10. [Amyotrophic lateral sclerosis, a heterogeneous disorder]. van Es MA; Kruitwagen-van Reenen ET; Schröder CD; Pasterkamp RJ; Veldink JH; van den Berg LH Ned Tijdschr Geneeskd; 2016; 160():A9658. PubMed ID: 26860749 [TBL] [Abstract][Full Text] [Related]
11. [Update on fundamental and clinical research in amyotrophic lateral sclerosis]. Pradat PF; Camdessanché JP; Carluer L; Cintas P; Corcia P; Danel-Brunaud V; Echaniz-Laguna A; Gonzalez J; Nicolas G; Vandenberghe N; Verschueren A; Rev Neurol (Paris); 2009; 165(6-7):532-41. PubMed ID: 19419744 [TBL] [Abstract][Full Text] [Related]
12. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914 [TBL] [Abstract][Full Text] [Related]
13. Motor neuron disease: systematic reviews of treatment for ALS and SMA. Orrell RW Br Med Bull; 2010; 93():145-59. PubMed ID: 20015852 [TBL] [Abstract][Full Text] [Related]
14. Evidence for a multimodal effect of riluzole in patients with ALS? de Jongh AD; van Eijk RPA; van den Berg LH J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1183-1184. PubMed ID: 30846539 [No Abstract] [Full Text] [Related]
15. [Amyotrophic lateral sclerosis: update on etiological treatment]. Ayach L; Curti C; Montana M; Pisano P; Vanelle P Therapie; 2013; 68(2):93-106. PubMed ID: 23773350 [TBL] [Abstract][Full Text] [Related]
16. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Brooks BR Ann Neurol; 2009 Jan; 65 Suppl 1():S17-23. PubMed ID: 19191306 [TBL] [Abstract][Full Text] [Related]
17. Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders. Mis MSC; Brajkovic S; Tafuri F; Bresolin N; Comi GP; Corti S Mol Neurobiol; 2017 Aug; 54(6):4466-4476. PubMed ID: 27349438 [TBL] [Abstract][Full Text] [Related]